Association of novel polymorphisms with the expression of SPARC in normal fibroblasts and with susceptibility to scleroderma

Arthritis and Rheumatism

Volumn 46, Issue 11, 2002, Pages 2990-2999

  Zhou, Xiaodong ^a   Tan, Filemon K ^a   Reveille, John D ^a   Wallis, Debra ^a   Milewicz, Dianna M ^a   Ahn, Chul ^a   Wang, Andrew ^a   Arnett, Frank C ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYTOSINE; GUANINE; MESSENGER RNA; OSTEONECTIN; THYMINE;

ALLELE; ARTICLE; CHROMOSOME 5Q; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DNA MICROARRAY; ETHNIC DIFFERENCE; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; FIBROBLAST CULTURE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GENOTYPE; HALF LIFE TIME; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; PHENOTYPE; POPULATION GENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAYNAUD PHENOMENON; SCLERODERMA; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN FIBROBLAST; UNTRANSLATED REGION; WESTERN BLOTTING;

BLOTTING, WESTERN; EXTRACELLULAR MATRIX PROTEINS; FIBROBLASTS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIANS, NORTH AMERICAN; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEONECTIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PULMONARY FIBROSIS; RAYNAUD DISEASE; RNA, MESSENGER; SCLERODERMA, SYSTEMIC;

EID: 0036846150     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10601     Document Type: Article

References (54)

1. Medsger TA Jr. Systemic sclerosis (scleroderma): Clinical aspects. In: Koopman WJ, editor. Arthritis and Allied Conditions. 13th Ed. Baltimore: Williams & Wilkins; 1997. p. 1433-64.
2. Johnson RW, Tew MB, Arnett FC. The genetics of systemic sclerosis. Curr Rheumatol Rep 2002;4:99-107.
3. Varga J, Jimenez SA. Pathogenesis of scleroderma: Cellular aspects. In: Clements PJ, Furst DE, editors. Systemic Sclerosis. Baltimore: Williams & Wilkins; 1996. p. 123-51.
4. Claman HN, Giorno RC, Seibold JR. Endothelial and fibroblastic activation in scleroderma: The myth of the "uninvolved skin." Arthritis Rheum 1991;34:1495-501.
5. Kuroda K, Shinkai H. Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 1997;289:567-72.
6. Alexander CM, Werb Z. Extracellular matrix degradation. In: Hay ED, editor. Cell Biology of the Extracellular Matrix. New York: Plenum Publishing; 1991. p. 255-302.
7. Reed MJ, Puolakkainen P, Lane TF, Dickerson D, Bornstein P, Sage EH. Differential expression of SPARC and thrombospondin 1 in wound repair: Immunolocalization and in situ hybridization. J Histochem Cytochem 1993;41:1467-77.
8. Hunzelmann N, Hafner M, Anders S, Krieg T, Nischt R. BM-40 (osteonectin, SPARC) is expressed both in the epidermal and in the dermal compartment of adult human skin. J Invest Dermatol 1998;110:122-6.
9. Motamed K. SPARC (osteonectin/BM-40). Int J Biochem Cell Biol 1999;31:1363-6.
10. Ledda MF, Adris S, Bravo AI, Kairiyama C, Bover L, Chernajovsky Y, et al. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med 1997;3:171-6.
11. Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 2000;6:1140-9.
12. Sage EH. Terms of attachment: SPARC and tumorigenesis. Nat Med 1997;3:144-6.
13. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, Podhajcer OL. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 1997;108:210-4.
14. Nakamura S, Kamihagi K, Satakeda H, Katayama M, Pan H, Okamoto H, et al. Enhancement of SPARC (osteonectin) synthesis in arthritic cartilage: Increased levels in synovial fluids from patients with rheumatoid arthritis and regulation by growth factors and cytokines in chondrocyte cultures. Arthritis Rheum 1996;39:539-51.
15. Frizell E, Liu SL, Abraham A, Ozaki I, Eghbali M, Sage EH, et al. Expression of SPARC in normal and fibrotic livers. Hepatology 1995;21:847-54.
16. Kuhn C, Mason RJ. Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis. Am J Pathol 1995;147:1759-69.
17. Vuorio T, Kahari VM, Black C, Vuorio E. Expression of osteonectin, decorin, and transforming growth factor-β genes in fibroblasts cultured from patients with systemic sclerosis and morphea. J Rheumatol 1991;18:247-51.
18. Duggan DJ, Bittner M, Chen Y, Meltzer P, Trent JM. Expression profiling using cDNA microarrays. Nat Genet 1999;21:10-4.
19. Zhou X, Tan FK, Xiong M, Milewicz DM, Feghali CA, Fritzler MJ, et al. Systemic sclerosis (scleroderma): Specific autoantigen genes are selectively overexpressed in scleroderma fibroblasts. J Immunol 2001;167:7126-33.
20. Arnett FC, Howard RF, Tan F, Moulds JM, Bias WB, Durban E, et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Arthritis Rheum 1996;39:1362-70.
21. Tan FK, Wang N, Kuwana M, Chakraborty R, Bona CA, Milewicz DM, et al. Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum 2001;44:893-901.
22. Reveille JD, Fischbach M, McNearney T, Friedman A, Aguilar MB, Lisse J, et al. Systemic sclerosis in three US ethnic groups: A comparison of clinical, sociodemographic, serologic and immunogenetic determinants. Semin Arthritis Rheum 2001;30:332-46.
23. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
24. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): Classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5.
25. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
26. Kahari VM, Olsen DR, Rhudy RW, Carrillo P, Chen YQ, Uitto J. Transforming growth factor-β up-regulates elastin gene expression in human skin fibroblasts: Evidence for post-transcriptional modulation. Lab Invest 1992;66:580-8.
27. Sham PC, Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995;59:97-105.
28. Abramson JH, Gahlinger PM. Computer Programs for Epidemiologists: PEPI 3.0. Stone Mountain (GA): USD Inc.; 1999.
29. Arnett FC. HLA and autoimmunity in scleroderma (systemic sclerosis). Int Rev Immunol 1995;12:107-28.
30. Wanstrat A, Wakeland E. The genetics of complex autoimmune disease: Non-MHC susceptibility genes. Nat Immunol 2001;2:802-9.
31. Herrmann K, Heckmann M, Kulozik M, Haustein UF, Krieg T. Steady-state mRNA levels of collagens I, III, fibronectin, and collagenase in skin biopsies of systemic sclerosis patients. J Invest Dermatol 1991;97:219-22.
32. Frittitta L, Ercolino T, Bozzali M, Argiolas A, Graci S, Santagati MG, et al. A cluster of three single nucleotide polymorphisms in the 3′-untranslated region of human glycoprotein PC-1 gene stabilizes PC-1 mRNA and is associated with increased PC-1 protein content and insulin resistance-related abnormalities. Diabetes 2001;50:1952-5.
33. Shaw G, Kamen R. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986;46:659-67.
34. Peppel K, Vinci JM, Baglioni C. The AU-rich sequences in the 3′ untranslated region mediate the increased turnover of interferon mRNA induced by glucocorticoids. J Exp Med 1991;173:349-55.
35. Francki A, Bradshaw AD, Bassuk JA, Howe CC, Couser WG, Sage EH. SPARC regulates the expression of collagen type I and transforming growth factor-β1 in mesangial cells. J Biol Chem 1999;274:32145-52.
36. Wrana JL, Overall CM, Sodek J. Regulation of the expression of a secreted acidic protein rich in cysteine (SPARC) in human fibroblasts by transforming growth factor beta: Comparison of transcriptional and post-transcriptional control with fibronectin and type I collagen. Eur J Biochem 1991;197:519-28.
37. Ford R, Wang G, Jannati P, Adler D, Racanelli P, Higgins PJ, et al. Modulation of SPARC expression during butyrate-induced terminal differentiation of cultured human keratinocytes: Regulation via a TGF-β-dependent pathway. Exp Cell Res 1993;206:261-75.
38. Strandjord TP, Madtes DK, Weiss DJ, Sage EH. Collagen accumulation is decreased in SPARC-null mice with bleomycin-induced pulmonary fibrosis. Am J Physiol 1999;277:L628-35.
39. Bradshaw AD, Reed MJ, Sage EH. SPARC-null mice exhibit accelerated cutaneous wound closure. J Histochem Cytochem 2002;50:1-10.
40. Shankavaram UT, DeWitt DL, Funk SE, Sage EH, Wahl LM. Regulation of human monocyte matrix metalloproteinases by SPARC. J Cell Physiol 1997;173:327-34.
41. Kupprion C, Motamed K, Sage EH. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J Biol Chem 1998;273:29635-40.
42. Raines EW, Lane TF, Iruela-Arispe ML, Ross R, Sage EH. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc Natl Acad Sci U S A 1992;89:1281-5.
43. Hasselaar P, Sage EH. SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. J Cell Biochem 1992;49:272-83.
44. Sasaki T, Hohenester E, Gohring W, Timpl R. Crystal structure and mapping by site-directed mutagenesis of the collagen-binding epitope of an activated form of BM-40/SPARC/osteonectin. EMBO J 1998;17:1625-34.
45. Reed MJ, Vernon RB, Abrass IB, Sage EH. TGF-β1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors. J Cell Physiol 1994;158:169-79.
46. Maurer P, Hohenadl C, Hohenester E, Gohring W, Timpl R, Engel J. The C-terminal portion of BM-40 (SPARC/osteonectin) is an autonomously folding and crystallisable domain that binds calcium and collagen IV. J Mol Biol 1995;253:347-57.
47. Kamihagi K, Katayama M, Ouchi R, Kato I. Osteonectin/SPARC regulates cellular secretion rates of fibronectin and laminin extracellular matrix proteins. Biochem Biophys Res Commun 1994;200:423-8.
48. Tremble PM, Lane TF, Sage EH, Werb Z. SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. J Cell Biol 1993;121:1433-44.
49. Sage EH, Bornstein P. Extracellular proteins that modulate cellmatrix interactions: SPARC, tenascin, and thrombospondin. J Biol Chem 1991;266:14831-4.
50. Bou-Gharios G, Osman J, Black C, Olsen I. Excess matrix accumulation in scleroderma is caused partly by differential regulation of stromelysin and TIMP-1 synthesis. Clin Chim Acta 1994;231:69-78.
51. Mattila L, Airola K, Ahonen M, Hietarinta M, Black C, Saarialho-Kere U, et al. Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts. J Invest Dermatol 1998;110:416-21.
52. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406:536-40.
53. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
54. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.